Cargando…

Low glucose metabolism in hepatocellular carcinoma with GPC3 expression

AIM: To investigate the relationship between glucose metabolism and glypican-3 (GPC3) expression in hepatocellular carcinoma (HCC). METHODS: Immunohistochemical staining of pathological samples for GPC3 and glucose transporter 1 (GLUT1), and whole-body (18)F-FDG PET/CT for measuring tumour glucose u...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, You-Cai, Yang, Chuan-Sheng, Zhou, Wen-Lan, Li, Hong-Sheng, Han, Yan-Jiang, Wang, Quan-Shi, Wu, Hu-Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787784/
https://www.ncbi.nlm.nih.gov/pubmed/29398870
http://dx.doi.org/10.3748/wjg.v24.i4.494
_version_ 1783295999723175936
author Li, You-Cai
Yang, Chuan-Sheng
Zhou, Wen-Lan
Li, Hong-Sheng
Han, Yan-Jiang
Wang, Quan-Shi
Wu, Hu-Bing
author_facet Li, You-Cai
Yang, Chuan-Sheng
Zhou, Wen-Lan
Li, Hong-Sheng
Han, Yan-Jiang
Wang, Quan-Shi
Wu, Hu-Bing
author_sort Li, You-Cai
collection PubMed
description AIM: To investigate the relationship between glucose metabolism and glypican-3 (GPC3) expression in hepatocellular carcinoma (HCC). METHODS: Immunohistochemical staining of pathological samples for GPC3 and glucose transporter 1 (GLUT1), and whole-body (18)F-FDG PET/CT for measuring tumour glucose uptake were performed in 55 newly diagnosed HCC patients. The maximum standard uptake value (SUV(max)) and tumour-to-non-tumourous liver uptake (T/NT) ratio were used to quantify (18)F-FDG uptake. In vitro (18)F-FDG uptake assay of GPC3-expressing HepG2 and non-GPC3-expressing RH7777 cells was used to examine the effect of GPC3 in cellular glucose metabolism. The relationships between GPC3 expression and (18)F-FDG uptake, GLUT1 expression, tumour differentiation, and other clinical indicators were analysed using Spearman rank correlation, univariate and multiple logistic regression analyses. RESULTS: Positive GPC3 expression was observed in 67.3% of HCC patients, including 75.0% of those with well or moderately differentiated HCC and 36.4% of those with poorly differentiated HCC. There was an inverse relationship between GPC3 expression and SUV(max) (Spearman correlation coefficient = -0.281, P = 0.038) and a positive relationship between GLUT1 expression and SUV(max) (Spearman correlation coefficient = 0.681, P < 0.001) in patients with HCC. Univariate analysis showed that two glucose metabolic parameters (SUV(max) and T/NT ratio), tumour differentiation, lymph node metastasis, and TNM stage were all significantly associated with GPC3 expression (P < 0.05), whereas GLUT1 expression, sex, age, tumour size, intrahepatic lesion number, and distant metastasis showed no statistical association (P > 0.05). Further multivariate analysis revealed that only the T/N ratio was significantly correlated with GPC3 expression in patients with HCC (P < 0.05). In vitro assay revealed that the uptake of (18)F-FDG in GPC3-expressing HepG2 cells was significantly lower than that of non-GPC3-expressing RH7777 cells (t = -20.352, P < 0.001). CONCLUSION: The present study demonstrated that GPC3 expression is inversely associated with glucose metabolism, suggesting that GPC3 may play a role in regulating glucose metabolism in HCC.
format Online
Article
Text
id pubmed-5787784
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-57877842018-02-02 Low glucose metabolism in hepatocellular carcinoma with GPC3 expression Li, You-Cai Yang, Chuan-Sheng Zhou, Wen-Lan Li, Hong-Sheng Han, Yan-Jiang Wang, Quan-Shi Wu, Hu-Bing World J Gastroenterol Retrospective Study AIM: To investigate the relationship between glucose metabolism and glypican-3 (GPC3) expression in hepatocellular carcinoma (HCC). METHODS: Immunohistochemical staining of pathological samples for GPC3 and glucose transporter 1 (GLUT1), and whole-body (18)F-FDG PET/CT for measuring tumour glucose uptake were performed in 55 newly diagnosed HCC patients. The maximum standard uptake value (SUV(max)) and tumour-to-non-tumourous liver uptake (T/NT) ratio were used to quantify (18)F-FDG uptake. In vitro (18)F-FDG uptake assay of GPC3-expressing HepG2 and non-GPC3-expressing RH7777 cells was used to examine the effect of GPC3 in cellular glucose metabolism. The relationships between GPC3 expression and (18)F-FDG uptake, GLUT1 expression, tumour differentiation, and other clinical indicators were analysed using Spearman rank correlation, univariate and multiple logistic regression analyses. RESULTS: Positive GPC3 expression was observed in 67.3% of HCC patients, including 75.0% of those with well or moderately differentiated HCC and 36.4% of those with poorly differentiated HCC. There was an inverse relationship between GPC3 expression and SUV(max) (Spearman correlation coefficient = -0.281, P = 0.038) and a positive relationship between GLUT1 expression and SUV(max) (Spearman correlation coefficient = 0.681, P < 0.001) in patients with HCC. Univariate analysis showed that two glucose metabolic parameters (SUV(max) and T/NT ratio), tumour differentiation, lymph node metastasis, and TNM stage were all significantly associated with GPC3 expression (P < 0.05), whereas GLUT1 expression, sex, age, tumour size, intrahepatic lesion number, and distant metastasis showed no statistical association (P > 0.05). Further multivariate analysis revealed that only the T/N ratio was significantly correlated with GPC3 expression in patients with HCC (P < 0.05). In vitro assay revealed that the uptake of (18)F-FDG in GPC3-expressing HepG2 cells was significantly lower than that of non-GPC3-expressing RH7777 cells (t = -20.352, P < 0.001). CONCLUSION: The present study demonstrated that GPC3 expression is inversely associated with glucose metabolism, suggesting that GPC3 may play a role in regulating glucose metabolism in HCC. Baishideng Publishing Group Inc 2018-01-28 2018-01-28 /pmc/articles/PMC5787784/ /pubmed/29398870 http://dx.doi.org/10.3748/wjg.v24.i4.494 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Li, You-Cai
Yang, Chuan-Sheng
Zhou, Wen-Lan
Li, Hong-Sheng
Han, Yan-Jiang
Wang, Quan-Shi
Wu, Hu-Bing
Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
title Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
title_full Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
title_fullStr Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
title_full_unstemmed Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
title_short Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
title_sort low glucose metabolism in hepatocellular carcinoma with gpc3 expression
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787784/
https://www.ncbi.nlm.nih.gov/pubmed/29398870
http://dx.doi.org/10.3748/wjg.v24.i4.494
work_keys_str_mv AT liyoucai lowglucosemetabolisminhepatocellularcarcinomawithgpc3expression
AT yangchuansheng lowglucosemetabolisminhepatocellularcarcinomawithgpc3expression
AT zhouwenlan lowglucosemetabolisminhepatocellularcarcinomawithgpc3expression
AT lihongsheng lowglucosemetabolisminhepatocellularcarcinomawithgpc3expression
AT hanyanjiang lowglucosemetabolisminhepatocellularcarcinomawithgpc3expression
AT wangquanshi lowglucosemetabolisminhepatocellularcarcinomawithgpc3expression
AT wuhubing lowglucosemetabolisminhepatocellularcarcinomawithgpc3expression